6 matches for your search in the start-up spotlight
rss
A total of sixteen teams presented their innovative ideas to almost 50 investors at the Munich start-up center.
18-Jul-2023
On July 13, 2023, the Munich Innovation and Start-up Center for Biotechnology (IZB) organized the 8th Life Science Pitch Day in cooperation with High-Tech Gründerfonds (HTGF), Leaps by Bayer, and Boehringer Ingelheim, which brought together sixteen biotech start-ups and project teams and almost ...
Product candidate ATR-002 could help hospital patients with COVID-19 avoid ventilation and intensive care treatment
27-Apr-2021
Atriva Therapeutics GmbH has secured up to €11.4 million in federal funding. The company, founded in 2015, announced today that it was selected for research funding from the German Federal Ministry of Education and Research (BMBF). Atriva will use the funds to advance its drug ATR-002 towards ...
EIB backs Atriva Therapeutics
22-Oct-2020
The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement to facilitate the company’s development and clinical testing of a novel therapy treating ...
Proceeds to be used to start Phase II study with ATR-002 in moderate to severe COVID-19 and clinical development in influenza and other respiratory viral infections
12-Aug-2020
Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new ...
04-Jan-2019
Atriva Therapeutics, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced the first closing in its ongoing series A financing round lead by Meneldor and High-Tech Gründerfonds (HTGF). The Company founders and management joined the round, also. ...
22-Sep-2017
The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 ...
